{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T12:10:06Z","timestamp":1795090206405,"version":"4.10.2"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Drug Policy"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.drugpo.2019.09.003","type":"journal-article","created":{"date-parts":[[2019,9,25]],"date-time":"2019-09-25T07:01:27Z","timestamp":1569394887000},"page":"76-83","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":164,"special_numbering":"C","title":["\u201cEverything is not right anymore\u201d: Buprenorphine experiences in an era of illicit fentanyl"],"prefix":"10.1016","volume":"74","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8995-0867","authenticated-orcid":false,"given":"Sydney M.","family":"Silverstein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6507-3866","authenticated-orcid":false,"given":"Raminta","family":"Daniulaityte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3059-9993","authenticated-orcid":false,"given":"Silvia S.","family":"Martins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon C.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4244-0173","authenticated-orcid":false,"given":"Robert G.","family":"Carlson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drugpo.2019.09.003_bib0001","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jsat.2016.08.002","article-title":"Non-Prescribed buprenorphine in New York City: Motivations for use, practices of diversion, and experiences of stigma","volume":"70","author":"Allen","year":"2016","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"2","key":"10.1016\/j.drugpo.2019.09.003_bib0002","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jsat.2010.05.004","article-title":"Expanding treatment capacity for opioid dependence with office-based treatment with buprenorphine: National surveys of physicians","volume":"39","author":"Arfken","year":"2010","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.drugpo.2019.09.003_bib0003","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.neuropharm.2017.10.016","article-title":"Fentanyl, fentanyl analogs and novel synthetic opioids: A comprehensive review","volume":"134","author":"Armenian","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.drugpo.2019.09.003_bib0004","series-title":"Disposition of toxic drugs and chemicals in man","author":"Baselt","year":"2011"},{"issue":"3","key":"10.1016\/j.drugpo.2019.09.003_bib0005","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/ADM.0b013e3182034e31","article-title":"Illicit use of buprenorphine\/naloxone among injecting and non-injecting opioid users","volume":"5","author":"Bazazi","year":"2011","journal-title":"Journal of Addiction Medicine"},{"issue":"5","key":"10.1016\/j.drugpo.2019.09.003_bib0006","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1111\/add.14522","article-title":"What should clinicians do as fentanyl replaces heroin?","volume":"114","author":"Bisaga","year":"2019","journal-title":"Addiction (Abingdon, England)"},{"issue":"6","key":"10.1016\/j.drugpo.2019.09.003_bib0007","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1111\/j.1360-0443.2008.02209.x","article-title":"Self\u2010treatment of opioid withdrawal using kratom (Mitragynia speciosa korth)","volume":"103","author":"Boyer","year":"2008","journal-title":"Addiction (Abingdon, England)"},{"key":"10.1016\/j.drugpo.2019.09.003_bib0008","series-title":"Proceedings of the paper presented at the college on problems of drug dependency annual meeting","article-title":"Unintentional drug overdose: Is more frequent use of non-prescribed buprenorphine associated with lower risk of overdose?","author":"Carlson","year":"2019"},{"key":"10.1016\/j.drugpo.2019.09.003_bib0009","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.drugpo.2017.05.023","article-title":"Exposure to fentanyl-contaminated heroin and overdose risk among illicit opioid users in Rhode Island: A mixed methods study","volume":"46","author":"Carroll","year":"2017","journal-title":"International Journal of Drug Policy"},{"issue":"6","key":"10.1016\/j.drugpo.2019.09.003_bib0010","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1097\/ADM.0000000000000436","article-title":"The more things change: Buprenorphine\/naloxone diversion continues while treatment remains inaccessible","volume":"12","author":"Carroll","year":"2018","journal-title":"Journal of Addiction Medicine"},{"key":"10.1016\/j.drugpo.2019.09.003_bib0011","series-title":"Increases in fentanyl drug confiscations and fentanyl-related overdose fatalities","year":"2015"},{"key":"10.1016\/j.drugpo.2019.09.003_bib0012","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.drugpo.2017.06.010","article-title":"Fentanyl in the US heroin supply: A rapidly changing risk environment","volume":"46","author":"Ciccarone","year":"2017","journal-title":"International Journal of Drug Policy"},{"key":"10.1016\/j.drugpo.2019.09.003_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2019.01.010","article-title":"The triple wave epidemic: Supply and demand drivers of the US opioid overdose crisis","author":"Ciccarone","year":"2019","journal-title":"International Journal of Drug Policy"},{"key":"10.1016\/j.drugpo.2019.09.003_bib0014","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.drugpo.2017.06.004","article-title":"Heroin uncertainties: Exploring users\u2019 perceptions of fentanyl-adulterated and-substituted \u2018heroin\u2019","volume":"46","author":"Ciccarone","year":"2017","journal-title":"International Journal of Drug Policy"},{"key":"10.1016\/j.drugpo.2019.09.003_bib0015","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.drugalcdep.2017.04.004","article-title":"Increases in self-reported fentanyl use among a population entering drug treatment: The need for systematic surveillance of illicitly manufactured opioids","volume":"177","author":"Cicero","year":"2017","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.drugpo.2019.09.003_bib0016","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.drugalcdep.2019.05.005","article-title":"Kratom as a substitute for opioids: Results from an online survey","volume":"202","author":"Coe","year":"2019","journal-title":"Drug and Alcohol Dependence"},{"issue":"4","key":"10.1016\/j.drugpo.2019.09.003_bib0017","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1097\/ADM.0b013e31829727b2","article-title":"Prior buprenorphine experience is associated with office-based buprenorphine treatment outcomes","volume":"7","author":"Cunningham","year":"2013","journal-title":"Journal of Addiction Medicine"},{"issue":"3","key":"10.1016\/j.drugpo.2019.09.003_bib0018","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.drugalcdep.2011.09.029","article-title":"Illicit use of buprenorphine in a community sample of young adult non-medical users of pharmaceutical opioids","volume":"122","author":"Daniulaityte","year":"2012","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.drugpo.2019.09.003_bib0019","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.drugpo.2019.05.020","article-title":"Street fentanyl use: Experiences, preferences, and concordance between self-reports and urine toxicology","volume":"71","author":"Daniulaityte","year":"2019","journal-title":"International Journal of Drug Policy"},{"issue":"34","key":"10.1016\/j.drugpo.2019.09.003_bib0020","doi-asserted-by":"crossref","first-page":"904","DOI":"10.15585\/mmwr.mm6634a3","article-title":"Overdose deaths related to fentanyl and its analogs\u2014Ohio","volume":"66","author":"Daniulaityte","year":"2017","journal-title":"MMWR. Morbidity and Mortality Weekly Report"},{"key":"10.1016\/j.drugpo.2019.09.003_bib0021","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.drugalcdep.2019.01.045","article-title":"Trends in fentanyl and fentanyl analogue-related overdose deaths-Montgomery County, Ohio, 2015\u20132017","volume":"198","author":"Daniulaityte","year":"2019","journal-title":"Drug and Alcohol Dependence,"},{"key":"10.1016\/j.drugpo.2019.09.003_bib0022","unstructured":"Daniulaityte, R., Nahhas, R. W., Silverstein, S. M., Martins, S., Zaragoza, A., Moeller, A. et\u00a0al. Patterns of non-prescribed buprenorphine and other opioid use among individuals with opioid use disorder: A latent class analysis. Drug and Alcohol Dependence, (in press)."},{"key":"10.1016\/j.drugpo.2019.09.003_bib0023","series-title":"National drug threat assessment","year":"2018"},{"issue":"2","key":"10.1016\/j.drugpo.2019.09.003_bib0024","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.drugpo.2006.11.006","article-title":"Harm reduction theory: Users\u2019 culture, micro-social indigenous harm reduction, and the self-organization and outside-organizing of users\u2019 groups","volume":"18","author":"Friedman","year":"2007","journal-title":"International Journal of Drug Policy"},{"key":"10.1016\/j.drugpo.2019.09.003_bib0025","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1111\/add.14614","article-title":"How the complex pharmacology of the fentanyls contributes to their lethality","volume":"114","author":"Gill","year":"2019","journal-title":"Addiction (Abingdon, England)"},{"key":"10.1016\/j.drugpo.2019.09.003_bib0026","series-title":"Discovery of grounded theory: Strategies for qualitative research","author":"Glaser","year":"2017"},{"key":"10.1016\/j.drugpo.2019.09.003_bib0027","first-page":"1","article-title":"Suspected involvement of fentanyl in prior overdoses and engagement in harm reduction practices among young adults who use drugs","author":"Goldman","year":"2019","journal-title":"Substance Abuse"},{"issue":"5","key":"10.1016\/j.drugpo.2019.09.003_bib0029","doi-asserted-by":"crossref","first-page":"346","DOI":"10.3109\/10550490903077820","article-title":"Uses of diverted methadone and buprenorphine by opioid-addicted individuals in baltimore, maryland","volume":"18","author":"Gwin Mitchell","year":"2009","journal-title":"American Journal on Addictions"},{"key":"10.1016\/j.drugpo.2019.09.003_bib0030","first-page":"105","article-title":"Use of microdoses for induction of buprenorphine treatment with overlapping full opioid agonist use: The Bernese method","volume":"99-","author":"H\u00e4mmig","year":"2016","journal-title":"Substance Abuse Rehabilitation 7"},{"issue":"2","key":"10.1016\/j.drugpo.2019.09.003_bib0031","doi-asserted-by":"crossref","first-page":"S59","DOI":"10.1016\/S0376-8716(03)00060-7","article-title":"Buprenorphine: How to use it right","volume":"70","author":"Johnson","year":"2003","journal-title":"Drug and Alcohol Dependence"},{"issue":"8","key":"10.1016\/j.drugpo.2019.09.003_bib0032","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1093\/jat\/bku086","article-title":"A series of forensic toxicology and drug seizure cases involving illicit fentanyl alone and in combination with heroin, cocaine or heroin and cocaine","volume":"38","author":"Marinetti","year":"2014","journal-title":"Journal of Analytic Toxicology"},{"key":"10.1016\/j.drugpo.2019.09.003_bib0033","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.socscimed.2015.06.032","article-title":"Heroin-related overdose: The unexplored influences of markets, marketing and source-types in the United States","volume":"140","author":"Mars","year":"2015","journal-title":"Social Science & Medicine"},{"issue":"2","key":"10.1016\/j.drugpo.2019.09.003_bib0034","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1080\/02791072.2017.1394508","article-title":"Sold as heroin: Perceptions and use of an evolving drug in Baltimore, MD","volume":"50","author":"Mars","year":"2018","journal-title":"Journal of Psychoactive Drugs"},{"key":"10.1016\/j.drugpo.2019.09.003_bib0035","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1111\/add.14587","article-title":"Fentanyl: The many challenges ahead","author":"Mars","year":"2019","journal-title":"Addiction 114"},{"key":"10.1016\/j.drugpo.2019.09.003_bib0036","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.drugpo.2016.01.009","article-title":"There's nothing here\u201d: Deindustrialization as risk environment for overdose","volume":"29","author":"McLean","year":"2016","journal-title":"International Journal of Drug Policy"},{"key":"10.1016\/j.drugpo.2019.09.003_bib0037","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.drugpo.2019.06.019","article-title":"\u201cThey're making it so hard for people to get help:\u201d motivations for non-prescribed buprenorphine use in a time of treatment expansion","volume":"71","author":"McLean","year":"2019","journal-title":"International Journal of Drug Policy"},{"issue":"6","key":"10.1016\/j.drugpo.2019.09.003_bib0038","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1080\/10826084.2018.1552303","article-title":"\u201cYou never know what you're getting\u201d: Opioid users\u2019 perceptions of fentanyl in southwest pennsylvania","volume":"54","author":"McLean","year":"2019","journal-title":"Substance Use & Misuse"},{"key":"10.1016\/j.drugpo.2019.09.003_bib0039","series-title":"How the gem city lost its luster and how it can get it back: A case study of Dayton, Ohio","author":"Millsap","year":"2018"},{"key":"10.1016\/j.drugpo.2019.09.003_bib0040","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jsat.2015.04.010","article-title":"Prior experience with non-prescribed buprenorphine: Role in treatment entry and retention","volume":"57","author":"Monico","year":"2015","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"1","key":"10.1016\/j.drugpo.2019.09.003_bib0042","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s13011-019-0195-4","article-title":"Higher doses of naloxone are needed in the synthetic opiod era","volume":"14","author":"Moss","year":"2019","journal-title":"Substance Abuse Treatment, Prevention, and Policy"},{"key":"10.1016\/j.drugpo.2019.09.003_bib0043","series-title":"2017 Ohio drug overdose data: General findings","year":"2018"},{"key":"10.1016\/j.drugpo.2019.09.003_bib0044","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.drugpo.2018.08.007","article-title":"Fentanyl test strips as an opioid overdose prevention strategy: Findings from a syringe services program in the Southeastern United States","volume":"63","author":"Peiper","year":"2019","journal-title":"International Journal of Drug Policy"},{"key":"10.1016\/j.drugpo.2019.09.003_bib0045","series-title":"Dreamland: The true tale of America's opiate epidemic","author":"Quinones","year":"2015"},{"issue":"2","key":"10.1016\/j.drugpo.2019.09.003_bib0046","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0955-3959(02)00007-5","article-title":"The \u2018risk environment\u2019: A framework for understanding and reducing drug-related harm","volume":"13","author":"Rhodes","year":"2002","journal-title":"International Journal of Drug Policy"},{"key":"10.1016\/j.drugpo.2019.09.003_bib0047","series-title":"Drug poisoning mortality: United States, 1999\u20132017","author":"Rossen","year":"2019"},{"issue":"1","key":"10.1016\/j.drugpo.2019.09.003_bib0048","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s12954-019-0311-9","article-title":"Harm reduction measures employed by people using opioids with suspected fentanyl exposure in Boston, Baltimore, and Providence","volume":"16","author":"Rouhani","year":"2019","journal-title":"Harm Reduction Journal"},{"issue":"1","key":"10.1016\/j.drugpo.2019.09.003_bib0049","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jsat.2010.03.014","article-title":"Self-treatment: Illicit buprenorphine use by opioid-dependent treatment seekers","volume":"39","author":"Schuman-Olivier","year":"2010","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"1\u20133","key":"10.1016\/j.drugpo.2019.09.003_bib0050","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.drugalcdep.2011.10.016","article-title":"The impact of buprenorphine on treatment of opioid dependence in a medicaid population: Recent service utilization trends in the use of buprenorphine and methadone","volume":"123","author":"Stein","year":"2012","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.drugpo.2019.09.003_bib0051","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2019.07.006","article-title":"Perceptions about fentanyl-adulterated heroin and overdose risk reduction behaviors among persons seeking treatment for heroin use","author":"Stein","year":"2019","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.drugpo.2019.09.003_bib0052","unstructured":"U.S. Census Bureau. (2017). ACA demographic and housing estimates. Accessible at:Https:\/\/factfinder.census.gov\/faces\/tableservices\/jsf\/pages\/productview.xhtml?pid=ACS_10_5YR_DP05 (Accessed 8 July 2019)."},{"issue":"2","key":"10.1016\/j.drugpo.2019.09.003_bib0053","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1016\/S0376-8716(03)00056-5","article-title":"The clinical pharmacology of buprenorphine: Extrapolating from the laboratory to the clinic","volume":"70","author":"Walsh","year":"2003","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.drugpo.2019.09.003_bib0054","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.drugalcdep.2015.12.031","article-title":"Methadone, buprenorphine and preferences for opioid agonist treatment: A qualitative analysis","volume":"160","author":"Yarborough","year":"2016","journal-title":"Drug and Alcohol Dependence"},{"issue":"23","key":"10.1016\/j.drugpo.2019.09.003_bib0056","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1176\/appi.pn.2018.11b12","article-title":"Factors to consider before prescribing buprenorphine","volume":"53","author":"Zagorski","year":"2018","journal-title":"Psychiatric News"},{"key":"10.1016\/j.drugpo.2019.09.003_bib0057","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.drugpo.2019.04.010","article-title":"Fentanyl shock: The changing geography of overdose in the United States","volume":"70","author":"Zoorob","year":"2019","journal-title":"International Journal of Drug Policy"}],"container-title":["International Journal of Drug Policy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0955395919302464?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0955395919302464?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T15:44:16Z","timestamp":1760629456000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0955395919302464"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":54,"alternative-id":["S0955395919302464"],"URL":"https:\/\/doi.org\/10.1016\/j.drugpo.2019.09.003","relation":{},"ISSN":["0955-3959"],"issn-type":[{"value":"0955-3959","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"\u201cEverything is not right anymore\u201d: Buprenorphine experiences in an era of illicit fentanyl","name":"articletitle","label":"Article Title"},{"value":"International Journal of Drug Policy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drugpo.2019.09.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}